ESR1 and breast cancer: This indicates that the low expression of ESR1, which is known to contribute to endocrine therapy resistance in ER+ breast cancer (Kim et al, 2011), only accounts for few samples displaying low estrogen response activity as detected by Cosinet, and high Cosinet scores do not indicate high ESR1 expression.